KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Leases (2019 - 2025)

Sarepta Therapeutics has reported Leases over the past 8 years, most recently at $125.5 million for Q4 2025.

  • Quarterly results put Leases at $125.5 million for Q4 2025, down 15.38% from a year ago — trailing twelve months through Dec 2025 was $125.5 million (down 15.38% YoY), and the annual figure for FY2025 was $125.5 million, down 15.38%.
  • Leases for Q4 2025 was $125.5 million at Sarepta Therapeutics, down from $139.2 million in the prior quarter.
  • Over the last five years, Leases for SRPT hit a ceiling of $148.3 million in Q4 2024 and a floor of $43.0 million in Q3 2022.
  • Median Leases over the past 5 years was $124.7 million (2024), compared with a mean of $100.6 million.
  • Biggest five-year swings in Leases: plummeted 50.38% in 2021 and later skyrocketed 210.11% in 2023.
  • Sarepta Therapeutics' Leases stood at $45.5 million in 2021, then surged by 42.66% to $65.0 million in 2022, then skyrocketed by 100.07% to $130.0 million in 2023, then rose by 14.13% to $148.3 million in 2024, then decreased by 15.38% to $125.5 million in 2025.
  • The last three reported values for Leases were $125.5 million (Q4 2025), $139.2 million (Q3 2025), and $143.0 million (Q2 2025) per Business Quant data.